MDS-O(Azacitidine tablets)

Therapeutic class: nucleoside metabolic inhibitor

Indication: Acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.